

DAFTAR PUSTAKA

1. Trihono PP, Alatas H, Tambunan T, Pardede S. Konsensus tata laksana sindrom nefrotik idiopatik pada anak. Edisi Kedua. Badan Penerbit Ikatan Dokter Anak Indonesia; 2012. 2–19 p.
2. Simatupang DF, Damanik MP, Sadjimin T. Perbedaan tingkat kualitas hidup anak dengan sindrom nefrotik primer kelainan minimal dan bukan kelainan minimal di RSUP Dr. Sardjito Yogyakarta. *Sari Pediatri* [Internet]. 2007 [cited 2025 Feb 28];9:220–6. Available from: <http://dx.doi.org/10.14238/sp9.3.2007.220-6>
3. Unit Kerja Koordinasi Nefrologi Ikatan Dokter Anak Indonesia. Konsensus tata laksana sindrom nefrotik idiopatik pada anak. Edisi Kedua. In Badan Penerbit Ikatan Dokter Anak Indonesia; 2012. p. 2–19.
4. Andersen RF, Thrane N, Noergaard K, Rytter L, Jespersen B, Rittig S. Early age at debut is a predictor of steroid-dependent and frequent relapsing nephrotic syndrome. *Pediatric Nephrology*. 2010;25:1299–304.
5. Agrwal S, Mantan M, Dabas A, Batra V V. Childhood Steroid-resistant Nephrotic Syndrome: Long-term Outcomes from a Tertiary Care Center. *Indian J Nephrol*. 2022;32.
6. Özlü SG, Demircin G, Tökmeci N, Çaltık Yılmaz A, Aydoğ Ö, Bülbül M, et al. Long-term prognosis of idiopathic nephrotic syndrome in children. *Ren Fail*. 2015;37:672–7.
7. Grimbert P, Audard V, Remy P, Lang P, Sahali D. Recent approaches to the pathogenesis of minimal-change nephrotic syndrome. *Nephrology Dialysis Transplantation*. 2003;18:245–8.
8. Ishikura K, Yoshikawa N, Nakazato H, Sasaki S, Nakanishi K, Matsuyama T, et al. Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trial. *Pediatric Nephrology*. 2015;30:459–68.
9. Laskin BL, Goebel J, Starke JR, Schauer DP, Eckman MH. Cost-Effectiveness of Latent Tuberculosis Screening Before Steroid Therapy for Idiopathic Nephrotic Syndrome in Children. *American Journal of Kidney Diseases* [Internet]. 2013;61:22–32. Available from: <https://doi.org/10.1053/j.ajkd.2012.06.004>
10. Tamez-Pérez HE. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. *World J Diabetes*. 2015;6:1073.
11. Bagga A, Mantan M. Nephrotic syndrome in children. *Indian J Med Res*. 2005;122:13–28.
12. Gulati S, Kher V, Gupta A, Arora P, Rai PK, Sharma RK. Spectrum of infections in Indian children with nephrotic syndrome. *Pediatr Nephrol*. 1995;9:431–4.
13. Wang C, Troost JP, Wang Y, Greenbaum LA, Gibson K, Trachtman H, et al. Determinants of medication adherence in childhood nephrotic syndrome and associations of adherence with clinical outcomes. *Pediatric Nephrology*. 2022;37:1585–95.
14. Panda BK, Sharma J, Srivastava P, Mishra A. Paediatric nephrotic syndrome: prednisolone treatment adherence and short-term outcomes. *Eur J Hosp Pharm*. 2013;20:346 LP – 350.
15. Gulati S, Sural S, Sharma RK, Gupta A, Gupta RK. Spectrum of adolescent-onset nephrotic syndrome in Indian children. *Pediatric Nephrology*. 2001;16:1045–8.



16. Kala U, Milner LS, Jacobs D, Thomson PD. Impact of tuberculosis in children with idiopathic nephrotic syndrome. *Pediatric Nephrology* [Internet]. 1993;7:392–5. Available from: <https://doi.org/10.1007/BF00857548>
17. Szymanik-Grzelak H, Kuźma-Mroczkowska E, Skrzypczyk P, Bielecka T, Kotula I, Pańczyk-Tomaszewska M. Tuberculosis infection in children with proteinuria/nephrotic syndrome. *Central European Journal of Immunology* [Internet]. 2017;42:318–23. Available from: <http://dx.doi.org/10.5114/ceji.2017.70977>
18. Tambunan T, Dewanti A, Madiyono B, Rahayoe N. Pulmonary tuberculosis in childhood nephrotic syndrome (A cross sectional study). *Paediatr Indones* [Internet]. 2001;41. Available from: <https://paediatricindonesiana.org/index.php/paediatrica-indonesiana/article/view/1247>
19. Ha T-S. Circulating Permeability Factors in Idiopathic Nephrotic Syndrome. *Child Kidney Dis* [Internet]. 2019;23:7–21. Available from: <https://doi.org/10.3339/jkspn.2019.23.1.7>
20. Santín S, Bullich G, Tazón-Vega B, García-Maset R, Giménez I, Silva I, et al. Clinical Utility of Genetic Testing in Children and Adults with Steroid-Resistant Nephrotic Syndrome. *Clinical Journal of the American Society of Nephrology*. 2011;6.
21. Albar H, Bilondatu F, Daud D. Risk factors for relapse in pediatric nephrotic syndrome. *Paediatr Indones*. 2018;58.
22. (ISKCD) I study of kidney diseases in children. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone: A report of the international study of kidney disease in children. *J Pediatr* [Internet]. 1981;98:561–4. Available from: <https://www.sciencedirect.com/science/article/pii/S0022347681807603>
23. Yang EM. Pathogenesis of Minimal Change Nephrotic Syndrome: A Review of the Underlying Molecular Mechanisms. *Child Kidney Dis*. 2019;23:1–6.
24. Claudio P, Gabriella M. Nephrotic syndrome: pathophysiology and consequences. *J Nephrol*. 2023;36:2179–90.
25. Cadnapaphornchai MA, Tkachenko O, Shchekochikhin D, Schrier RW. The nephrotic syndrome: pathogenesis and treatment of edema formation and secondary complications. *Pediatric Nephrology* [Internet]. 2014;29:1159–67. Available from: <https://doi.org/10.1007/s00467-013-2567-8>
26. Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. *Pediatric Nephrology* [Internet]. 2020;35:1529–61. Available from: <https://doi.org/10.1007/s00467-020-04519-1>
27. International study of kidney diseases in children (ISKCD). The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone: A report of the international study of kidney disease in children. *J Pediatr*. 1981;98:561–4.
28. Asinobi AO, Ademola AD, Okolo CA, Yaria JO. Trends in the histopathology of childhood nephrotic syndrome in Ibadan Nigeria: preponderance of idiopathic focal segmental glomerulosclerosis. *BMC Nephrol* [Internet]. 2015;16:213. Available from: <https://doi.org/10.1186/s12882-015-0208-0>
29. KDIGO. KDIGO Clinical practice guideline for glomerulonephritis. *Kidney Int Suppl*. 2014;19:4477–83.



30. Liu ID, Willis NS, Craig JC, Hodson EM. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. *Cochrane Database of Systematic Reviews*. 2019;
31. Lee JM, Kronbichler A, Shin J Il, Oh J. Current understandings in treating children with steroid-resistant nephrotic syndrome. *Pediatric Nephrology*. 2021;36:747–61.
32. Jiang B, Cheng Z, Liu F, Li Q, Fu H, Mao J. Renoprotection with sodium-glucose cotransporter-2 inhibitors in children: Knowns and unknowns. *Nephrology* [Internet]. 2022;27:126–32. Available from: <https://doi.org/10.1111/nep.13979>
33. Liu J, Cui J, Fang X, Chen J, Yan W, Shen Q, et al. Efficacy and Safety of Dapagliflozin in Children With Inherited Proteinuric Kidney Disease: A Pilot Study. *Kidney Int Rep* [Internet]. 2022;7:638–41. Available from: <https://doi.org/10.1016/j.ekir.2021.12.019>
34. N RM, E AC, Jonathan B, Stewart B, Pietro C, Dong-Wan C, et al. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. *New England Journal of Medicine* [Internet]. 2023;389:2436–45. Available from: <https://doi.org/10.1056/NEJMoa2308550>
35. Trautmann A, Schnaidt S, Lipska-Ziętkiewicz BS, Bodria M, Ozaltin F, Emma F, et al. Long-term outcome of steroid-resistant nephrotic syndrome in children. *Journal of the American Society of Nephrology*. 2017;28:3055–65.
36. Mekahli D, Liutkus A, Ranchin B, Yu A, Bessenay L, Girardin E, et al. Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: A multicenter study. *Pediatric Nephrology*. 2009;24:1525–32.
37. Shatat IF, Becton LJ, Woroniecki RP. Hypertension in Childhood Nephrotic Syndrome . Vol. 7, *Frontiers in Pediatrics* . 2019.
38. Hari P, Khandelwal P, Smoyer WE. Dyslipidemia and cardiovascular health in childhood nephrotic syndrome. *Pediatric Nephrology*. 2020;35:1601–19.
39. Ruvertoni M. Striae in Children and Adolescents. In: *Harper's Textbook of Pediatric Dermatology*. 2019. p. 1172–4.
40. Thalghagoda S, Jayaweera H, Illangasekera Y, Abeyagunawardena A, Abeyagunawardena S, Affiliation A. The effect of alternate-day corticosteroids on linear growth in childhood nephrotic syndrome. 2019;
41. Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: A review of glucocorticoid pharmacology and bone health. *J Am Acad Dermatol*. 2017;76:1–9.
42. Danner E, Joeckel R, Michalak S, Phillips S, Goday PS. Weight velocity in infants and children. *Nutrition in Clinical Practice*. 2009;24:76–9.
43. Bamba V, Kelly A. Assessment of growth. In: Kliegman R, St. Geme III JW, Schor N, Stanton B, Behrman R, editors. *Nelson Textbook of Pediatrics*. 22nd ed. Elsevier; 2025. p. 172–8.
44. Olonan L, Pangilinan C, Yatco M. Steroid-induced cataract and glaucoma in pediatric patients with nephrotic syndrome. *Ophthalmology*. 2009;59–62.
45. Vergara ACZ, Pérez IST. Prolonged use of Furosemide in Pediatrics. *Clinical Research in Pediatrics*. 2018;1:1–4.
46. Varma H, Sharma A, Santhiya S, Dawman L, Tiewsoh K. Furosemide-induced tubular dysfunction responding to prostaglandin synthesis inhibitor therapy in a child with nephrotic syndrome. *CEN Case Rep*. 2018;7.



47. Qavi AH, Kamal R, Schrier R. Clinical Use of Diuretics in Heart Failure, Cirrhosis, and Nephrotic Syndrome. *Int J Nephrol*. 2015;2015:975934.
48. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. *Pediatrics*. 2017;140:e20171904.
49. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. *Pediatrics* [Internet]. 2017;140:e20171904–e20171904. Available from: <https://doi.org/10.1542/peds.2017-1904>
50. Ding W, Cheung W, Mak R. Impact of obesity on kidney function and blood pressure in children. *World J Nephrol*. 2015;4:223–9.
51. Sekarwana N. Chronic kidney disease. In: *Kompndium Nefrologi Anak*. Jakarta: Badan Penerbit Ikatan Dokter Anak Indonesia; 2011. p. 215–22.
52. Tao M, Wang H-P, Sun J, Tian J. Progress of research on dyslipidemia accompanied by nephrotic syndrome. *Chronic Dis Transl Med*. 2020;6:182–7.
53. Grimbert P, Audard V, Remy P, Lang P, Sahali D. Recent approaches to the pathogenesis of minimal-change nephrotic syndrome. *Nephrology Dialysis Transplantation* [Internet]. 2003;18:245–8. Available from: <https://doi.org/10.1093/ndt/18.2.245>
54. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. *Petunjuk teknis tata laksana tuberkulosis pada anak dan remaja*. Jakarta: Kementerian Kesehatan RI; 2023.
55. Kementerian Kesehatan Republik Indonesia. *Petunjuk teknis penanganan infeksi laten tuberkulosis*. Jakarta: Kementerian Kesehatan Republik Indonesia; 2020.
56. Direktorat Pencegahan dan Pengendalian Penyakit Kementerian Kesehatan RI. *Buku Petunjuk TB HIV bagi Petugas Kesehatan*. Jakarta: Kementrian Kesehatan Republik Indonesia; 2016.
57. Kementerian Kesehatan Republik Indonesia. *Petunjuk teknis penanganan infeksi laten tuberkulosis*. Jakarta: Kementerian Kesehatan Republik Indonesia; 2020.
58. Bermejo V, de la Vega M, Benitez A, Rodriguez C. Tuberculosis in patients with induced immunosuppression in an endemic country. *International Journal of Infectious Diseases* [Internet]. 2018;73:102–3. Available from: <https://doi.org/10.1016/j.ijid.2018.04.3653>
59. Lancella L, Galli L, Chiappini E, Montagnani C, Gabiano C, Garazzino S, et al. Recommendations Concerning the Therapeutic Approach to Immunocompromised Children With Tuberculosis. *Clin Ther* [Internet]. 2016;38:180–90. Available from: <https://doi.org/10.1016/j.clinthera.2015.10.012>
60. Li S, Zhang M, Chen L, Wang Z. An Implication of Relationship between Tuberculosis and Primary Nephrotic Syndrome. *Int J Artif Organs* [Internet]. 2015;38:178–83. Available from: <https://doi.org/10.5301/ijao.5000402>
61. Gulati S, Kher V, Gulati K, Arora P, Gujral R. Tuberculosis in childhood nephrotic syndrome in India. *Pediatr Nephrol*. 1997;11:695–8.
62. Torpiano P, Holwill S, Pace D. Mesangiocapillary glomerulonephritis complicating pulmonary tuberculosis. *CEN Case Rep*. 2022;11:17–21.
63. Nassih H, El Qadiry R, Bourrahout A, Ait Sab I. Challenges in the Diagnosis and Management of Nephrotic Syndrome in a Child With Multisystemic Tuberculosis. *Glob Pediatr Health* [Internet]. 2022;9:2333794X221078703. Available from: <https://doi.org/10.1177/2333794X221078703>



64. Tambunan T, Dewanti A, Madiyono B, Rahayoe N. Pulmonary tuberculosis in childhood nephrotic syndrome (A cross sectional study). *Paediatr Indones* [Internet]. 2001;41. Available from: <https://paediatricaindonesiana.org/index.php/paediatricaindonesiana/article/view/1247>
65. Carter JC, Wrede JE. Overview of Sleep and Sleep Disorders in Infancy and Childhood. *Pediatr Ann* [Internet]. 2017;46:e133–8. Available from: <https://search.ebscohost.com/login.aspx?direct=true&db=mnh&AN=28414394&site=ehost-live>
66. Darwish AH, Abdel-Nabi H. Sleep disorders in children with chronic kidney disease. *Int J Pediatr Adolesc Med* [Internet]. 2016;3:112–8. Available from: <https://www.sciencedirect.com/science/article/pii/S2352646716300278>
67. Walker RG, Obeid J, Nguyen T, Ploeger H, Proudfoot NA, Bos C, et al. Sedentary Time and Screen-Based Sedentary Behaviors of Children With a Chronic Disease. *Pediatr Exerc Sci* [Internet]. 2015;27:219–25. Available from: <https://journals.humankinetics.com/view/journals/pes/27/2/article-p219.xml>
68. Kansagra S. Sleep Disorders in Adolescents. *Pediatrics* [Internet]. 2020;145:S204–9. Available from: <https://doi.org/10.1542/peds.2019-2056I>
69. Krishna J, Kalra M, McQuillan ME. Sleep Disorders in Childhood. *Pediatr Rev* [Internet]. 2023;44:189–202. Available from: <https://doi.org/10.1542/pir.2022-005521>
70. Tune BM, Kirpekar R, Sibley RK, Reznik VM, Griswold WR, Mendoza SA. Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. *Clin Nephrol* [Internet]. 1995;43:84–88. Available from: <http://europepmc.org/abstract/MED/7736683>
71. Niaudet P, Habib R. Cyclosporine in the treatment of idiopathic nephrosis. *Journal of the American Society of Nephrology* [Internet]. 1994;5. Available from: https://journals.lww.com/jasn/fulltext/1994/10000/cyclosporine_in_the_treatment_of_idiopathic.2.aspx
72. Ishikura K, Ikeda M, Hattori S, Yoshikawa N, Sasaki S, Iijima K, et al. Effective and safe treatment with cyclosporine in nephrotic children: A prospective, randomized multicenter trial. *Kidney Int* [Internet]. 2008;73:1167–73. Available from: <https://www.sciencedirect.com/science/article/pii/S0085253815528469>
73. Samuel S, Bitzan M, Zappitelli M, Dart A, Mammen C, Pinsk M, et al. Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis: Management of Nephrotic Syndrome in Children. *American Journal of Kidney Diseases* [Internet]. 2014;63:354–62. Available from: <https://www.sciencedirect.com/science/article/pii/S0272638613015564>
74. Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. *J Pediatr* [Internet]. 1994;125:981–6. Available from: <https://www.sciencedirect.com/science/article/pii/S0022347605820207>
75. Ehrich JHH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J. Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. *Nephrology Dialysis Transplantation* [Internet]. 2007;22:2183–93. Available from: <https://doi.org/10.1093/ndt/gfm092>



76. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. *Kidney Int* [Internet]. 1999;56:2220–6. Available from: <https://doi.org/10.1046/j.1523-1755.1999.00778.x>
77. Ingulli E, Singh A, Baqi N, Ahmad H, Moazami S, Tejani A. Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis. *Journal of the American Society of Nephrology* [Internet]. 1995;5. Available from: https://journals.lww.com/jasn/fulltext/1995/04000/aggressive,_long_term_cyclosporine_therapy_for.14.aspx
78. Büscher AK, Kranz B, Büscher R, Hildebrandt F, Dworniczak B, Pennekamp P, et al. Immunosuppression and Renal Outcome in Congenital and Pediatric Steroid-Resistant Nephrotic Syndrome. *Clinical Journal of the American Society of Nephrology* [Internet]. 2010;5. Available from: https://journals.lww.com/cjasn/fulltext/2010/11000/immunosuppression_and_renal_outcome_in_congenital.30.aspx
79. Büscher AK, Beck BB, Melk A, Hoefele J, Kranz B, Bamborschke D, et al. Rapid Response to Cyclosporin A and Favorable Renal Outcome in Nongenetic Versus Genetic Steroid-Resistant Nephrotic Syndrome. *Clinical Journal of the American Society of Nephrology* [Internet]. 2016;11. Available from: https://journals.lww.com/cjasn/fulltext/2016/02000/rapid_response_to_cyclosporin_a_and_favorable.8.aspx
80. Sethna CB, Gipson DS. Treatment of FSGS in Children. *Adv Chronic Kidney Dis* [Internet]. 2014;21:194–9. Available from: <https://www.sciencedirect.com/science/article/pii/S1548559514000135>
81. Kim J, Patnaik N, Chorny N, Frank R, Infante L, Sethna C. Second-Line Immunosuppressive Treatment of Childhood Nephrotic Syndrome: A Single-Center Experience. *Nephron Extra* [Internet]. 2014;4:8–17. Available from: <https://doi.org/10.1159/000357355>
82. Tamborlane W V, Laffel LM, Shehadeh N, Isganaitis E, Van Name M, Ratnayake J, et al. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. *Lancet Diabetes Endocrinol* [Internet]. 2022;10:341–50. Available from: [https://doi.org/10.1016/S2213-8587\(22\)00052-3](https://doi.org/10.1016/S2213-8587(22)00052-3)
83. Dos Santos Borges R, Conegundes AF, Haikal De Paula L, Lara Santos R, Alves SN, MacHado RA, et al. Efficacy and Safety of SGLT2 Inhibitors in Pediatric Patients and Young Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Vol. 2024, Pediatric Diabetes. John Wiley and Sons Inc; 2024.
84. Gross O, Boeckhaus J, Weber LT, Heerspink HJL, Simon JF, Ahmed R, et al. Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport. *Nephrology Dialysis Transplantation* [Internet]. 2024;gfae180. Available from: <https://doi.org/10.1093/ndt/gfae180>
85. Toruan YL, Trihono P, Sitorus R, Dwipoerwantoro P. Ocular complications in pediatric nephrotic syndrome treated with corticosteroids. *Paediatr Indones* [Internet]. 2024;64. Available from: <https://www.paediatricaindonesiana.org/index.php/paediatricaindonesiana/article/view/3297>



86. Liu ID, Willis NS, Craig JC, Hodson EM. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. *Cochrane Database of Systematic Reviews* [Internet]. 2019; Available from: <https://doi.org/10.1002/14651858.CD003594.pub6>
87. Ruggenti P, Cravedi P, Chianca A, Caruso MR, Remuzzi G. Achieving remission of proteinuria in childhood CKD. *Pediatric Nephrology*. 2017;32:321–30.
88. Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. *Arthritis and Rheumatology*. 2017;69:1521–37.
89. Brustad N, Yousef S, Stokholm J, Bønnelykke K, Bisgaard H, Chawes BL. Safety of High-Dose Vitamin D Supplementation Among Children Aged 0 to 6 Years: A Systematic Review and Meta-analysis. *JAMA Netw Open* [Internet]. 2022;5:e227410–e227410. Available from: <https://doi.org/10.1001/jamanetworkopen.2022.7410>
90. Caronan-Parallag RG, Uy TMZ, Anacleto FE, Aragon EET, Resontoc LPR. Vitamin D Supplementation and Bone Health in Children with Nephrotic Syndrome: A Systematic Review and Meta-Analysis. *Asian Journal of Pediatric Nephrology* [Internet]. 2021;4. Available from: https://journals.lww.com/ajpn/fulltext/2021/04010/vitamin_d_supplementation_and_bone_health_in.3.aspx
91. Prescott WA, Streetman DD, Streetman DS. The Potential Role of HMG-CoA Reductase Inhibitors in Pediatric Nephrotic Syndrome. *Annals of Pharmacotherapy* [Internet]. 2004;38:2105–14. Available from: <https://doi.org/10.1345/aph.1D587>
92. KDIGO. KDIGO Clinical practice guideline for glomerulonephritis. *Kidney Int Suppl*. 2014;19:4477–83.
93. Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. *Kidney Int* [Internet]. 2021;100:S1–276. Available from: <https://doi.org/10.1016/j.kint.2021.05.021>
94. Oh GJ, Waldo A, Paez-Cruz F, Gipson PE, Pesenson A, Selewski DT, et al. Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease. *Kidney Int Rep* [Internet]. 2019;4:1608–16. Available from: <https://www.sciencedirect.com/science/article/pii/S2468024919314755>
95. Kumar M, Ghunawat J, Saikia D, Manchanda V. Incidence and risk factors for major infections in hospitalized children with nephrotic syndrome. *Brazilian Journal of Nephrology* [Internet]. 2019;41:526–33. Available from: <https://www.bjnephrology.org/article/incidencia-e-fatores-de-risco-para-infeccoes-graves-em-criancashospitalizadas-com-sindrome-nefroticas/>
96. Shukla J, Gupta A, Kalra R. Quality of Life of Children with Idiopathic Nephrotic Syndrome: A Review. *Indian J Nephrol* [Internet]. 0. Available from: https://doi.org/10.25259/IJN_5_2024
97. Aier A, Pais P, Raman V. Psychosocial Functioning and Health-Related Quality of Life in Children with Nephrotic Syndrome: Preliminary Findings. *Journal of Indian Association for Child and Adolescent Mental Health* [Internet]. 2022;18:306–14. Available from: <https://doi.org/10.1177/09731342231166176>



98. Samsel C, Muriel AC. Risk factors and treatment for steroid-related mood and behavior symptoms in preschool children with leukemia: A case series. *Pediatr Blood Cancer*. 2017;64:343–5.